Drug Cost Management Report - Seroquel, by AstraZeneca - Brief Article
* Seroquel, by AstraZeneca, may help schizophrenia patients achieve better outcomes than do other antipsychotics because it does not cause a dose-related increase in extrapyramidal symptoms (EPS)–movement disorder side effects. EPS are frequent and debilitating side effects associated with other antipsychotics that can lead to poor treatment compliance, which can in turn lead to increased hospitalizations and poor quality of life for the undertreated patient.
Related Results
FDA warns of Seroquel, Serzone errors
Kentucky Medicaid puts Zyprexa on prior authorization
US clears AstraZeneca treatment for mania
Bipolar drug Seroquel receives US approval
Shares and Market Report: Ailing drug groups extend FTSE 100 losing
The research was published in the Annals of Clinical Psychiatry. Information: Antonia Betts, antonia.betts@shirehealthinternational.com.
COPYRIGHT 2002 Atlantic Information Services, Inc.
COPYRIGHT 2003 Gale Group
